Brief: Knight Therapeutics Says Has Exclusive Right To Commercialize Ibsrela In Canada Under Terms Of A License Agreement Entered Into With Ardelyx
02/03/2021 01:31
March 1 (Reuters) - Knight Therapeutics Inc GUD.TO :
* CANADIAN COMMERCIAL AVAILABILITY OF IBSRELA, THERAPY FOR
TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION(IBS-C)
IN ADULTS
* KNIGHT HAS EXCLUSIVE RIGHT TO COMMERCIALIZE IBSRELA IN
CANADA
UNDER TERMS OF A LICENSE AGREEMENT ENTERED INTO WITH ARDELYX
Source text for Eikon: ID:nGNX3wwtL2
Further company coverage: GUD.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Knight Therapeutics
See all newsBrief: Knight Therapeutics Announces Regulatory Approval Of Niktimvo In Brazil
Brief: Knight Therapeutics - Launches Tavalisse In Brazil For Chronic Immune Thrombocytopenia
Brief: Knight Therapeutics Enters Into Exclusive Distribution Agreement With Kyowa Kirin International For Poteligeo® (Mogamulizumab)
Brief: Knight Therapeutics Announces Regulatory Approval Of Tavalisse® In Colombia
Brief: Knight Therapeutics Announces Supplemental Regulatory Submission For Minjuvi In Brazil